56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma
ESMO Rare Cancers · 2026-03 · 5 · 100262
DOI: 10.1016/j.esmorc.2026.100262 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von I. Micheletto und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Micheletto, I., Serna, S. L., Labaig, P. J., Cheng, L., Harrington, K., Wong, K., & Newbold, K. (2026). 56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma. ESMO Rare Cancers, 5, 100262. https://doi.org/10.1016/j.esmorc.2026.100262
Vancouver
Micheletto I, Serna SL, Labaig PJ, Cheng L, Harrington K, Wong K, et al. 56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma. ESMO Rare Cancers. 2026;5:100262. doi:10.1016/j.esmorc.2026.100262
BibTeX
@article{Micheletto2026,
author = {Micheletto, I. and Serna, S. Llop and Labaig, P. Jimenez and Cheng, L. and Harrington, K.J. and Wong, K.H.H. and Newbold, K.},
title = {56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100262},
doi = {10.1016/j.esmorc.2026.100262}
}
EUVIMED